Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders, is advancing its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for multiple sclerosis (MS). The announcement came during a return appearance by co-founder and executive co-chair Anthony Durkacz on The BioMedWire Podcast, where he discussed the program and the company's consumer health asset, unbuzzd(TM).
Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models—the underlying mechanism of MS. According to Durkacz, the upcoming Phase 2 trial will be the first time the drug is tested in patients with multiple sclerosis, a critical step in translating preclinical promise into clinical evidence. The trial's progress could provide a significant catalyst for Quantum BioPharma, which is dedicated to building a portfolio of innovative assets for challenging conditions.
Beyond its pharmaceutical pipeline, Quantum BioPharma holds a substantial stake in Unbuzzd Wellness Inc., the company commercializing unbuzzd(TM), an over-the-counter product designed to accelerate alcohol metabolism. Quantum retains 19.84% ownership of Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Durkacz highlighted clinical results for unbuzzd(TM) and the commercial opportunity surrounding the product, which targets the large and growing market for alcohol misuse solutions.
The dual focus on a high-risk, high-reward drug candidate and a consumer product with near-term revenue potential may appeal to investors seeking diversified exposure to the biotech sector. Quantum's strategy of retaining 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses further underscores its commitment to long-term value creation in both therapeutic and consumer health spaces.
For those following the company, the latest news and updates relating to QNTM are available in its newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/ovRTM.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. Additional corporate communications solutions are also offered.
For investors, the key takeaway is that Quantum BioPharma is progressing a potentially first-in-class MS therapy while also holding a royalty interest in a consumer product that could generate steady cash flow. If Lucid-MS succeeds in Phase 2, it could validate the company's approach to myelin repair and open doors to partnerships or licensing deals. Meanwhile, unbuzzd(TM)'s commercial performance will be watched as a source of non-dilutive funding for the company's drug development efforts. As with any clinical-stage biotech, risks remain, but the dual strategy offers multiple shots on goal. The full terms of use and disclaimers applicable to BioMedWire content are available at https://www.BioMedWire.com/Disclaimer.
